Tadalafil (Generic) and Hormonal Contraceptives: Is There a Real Interaction?

How Tadalafil Is Metabolized and Why CYP3A4 Matters

Tadalafil belongs to the phosphodiesterase type 5 (PDE5) inhibitor class. The liver processes it almost entirely through the cytochrome P450 3A4 (CYP3A4) enzyme pathway [1]. This matters because drugs that strongly inhibit or induce CYP3A4 can raise or lower tadalafil blood levels, respectively. Hormonal contraceptives, however, do not fall into the category of strong CYP3A4 modulators.

Ethinyl estradiol (EE), the estrogen component in most combined oral contraceptives, undergoes first-pass metabolism via CYP3A4 and sulfotransferase pathways [2]. It acts as a weak, clinically insignificant inhibitor of CYP3A4 at therapeutic doses. Progestins such as norethindrone, levonorgestrel, and drospirenone are also CYP3A4 substrates but do not inhibit the enzyme at concentrations reached during standard contraceptive use [3]. Because neither ethinyl estradiol nor common progestins meaningfully alter CYP3A4 activity, the metabolic clearance of tadalafil remains unchanged.

The FDA-approved prescribing information for tadalafil states directly: "Tadalafil did not affect the pharmacokinetics of an oral contraceptive (norethindrone/ethinyl estradiol)" [1]. This finding removes the theoretical concern that substrate competition at CYP3A4 could create a bidirectional interaction.

What the FDA Label Drug Interaction Study Showed

The tadalafil prescribing information describes a dedicated pharmacokinetic study in healthy female volunteers [1]. Participants received a combined oral contraceptive (norethindrone 1 mg / ethinyl estradiol 35 mcg) to steady state, then received a single dose of tadalafil. Researchers measured the area under the curve (AUC) and peak concentration (Cmax) for both the contraceptive hormones and tadalafil.

Results were unambiguous. Tadalafil did not change ethinyl estradiol AUC or Cmax. Norethindrone exposure also remained within its normal range. The 90% confidence intervals for the geometric mean ratios of AUC and Cmax fell entirely within the standard bioequivalence window of 80% to 125% [1]. In the reverse direction, steady-state oral contraceptive use did not alter tadalafil clearance or half-life.

No adverse hormonal effects were observed. Ovulation suppression markers remained consistent with expected oral contraceptive activity. This study provides Level 1 pharmacokinetic evidence that the two drugs do not interact.

Pharmacodynamic Considerations: PDE5 Inhibition and Hormonal Pathways

Beyond metabolism, a pharmacodynamic interaction would require the two drugs to influence overlapping physiologic pathways in a harmful way. They do not. Tadalafil works by blocking PDE5, which degrades cyclic guanosine monophosphate (cGMP) in vascular smooth muscle [4]. This produces vasodilation, primarily in the corpus cavernosum and the pulmonary vasculature.

Hormonal contraceptives act through an entirely different axis. Combined pills suppress the hypothalamic-pituitary-ovarian (HPO) axis by providing exogenous estrogen and progestin, which inhibits gonadotropin-releasing hormone (GnRH) pulsatility and prevents the luteinizing hormone (LH) surge needed for ovulation [5]. Progestin-only methods thicken cervical mucus and thin the endometrium.

These two mechanisms operate independently. PDE5 inhibition does not interfere with HPO axis suppression, GnRH signaling, or progesterone receptor binding. The Endocrine Society's 2017 guideline on testosterone therapy in men noted no fertility-related pharmacodynamic concern with PDE5 inhibitors in either sex [6]. While that guideline focuses on male patients, the pharmacodynamic principle applies: PDE5 inhibition and hormonal contraception do not share a common effector pathway.

Does the Type of Hormonal Contraceptive Matter?

The FDA interaction study used a combined oral contraceptive specifically. Patients and clinicians often ask whether the finding extends to other delivery systems: the patch (norelgestromin/EE), the vaginal ring (etonogestrel/EE), hormonal IUDs (levonorgestrel), the implant (etonogestrel), and injectable medroxyprogesterone acetate (DMPA).

The answer is yes, and the reasoning is pharmacokinetic. All of these methods deliver progestins and/or estrogens that are CYP3A4 substrates but not clinically relevant CYP3A4 inhibitors or inducers [3]. The serum concentrations of hormones achieved by non-oral routes are generally lower than or comparable to those from oral pills, because non-oral delivery avoids the high portal vein concentrations responsible for first-pass hepatic effects [7]. If oral contraceptives at full first-pass exposure produce no interaction, lower-exposure non-oral methods will not either.

Levonorgestrel-releasing IUDs present the clearest case. They achieve serum levonorgestrel levels of approximately 150 to 200 pg/mL [8], far below the systemic concentrations from oral levonorgestrel (approximately 2 to 6 ng/mL) [3]. A drug interaction with tadalafil at these trace systemic levels is pharmacologically implausible.

DMPA (depot medroxyprogesterone acetate) is likewise safe to combine. Medroxyprogesterone is metabolized by CYP3A4 but is not a meaningful inhibitor of the enzyme [9]. No dose adjustment of tadalafil is warranted with any hormonal contraceptive formulation.

Why Tadalafil Is Sometimes Prescribed to Women

Though tadalafil is FDA-approved only for erectile dysfunction and benign prostatic hyperplasia in men, off-label use in women is an active area of research. Two clinical contexts drive this interest: female sexual arousal disorder (FSAD) and Raynaud phenomenon.

A randomized controlled trial by Caruso et al. (2006) studied tadalafil 20 mg in premenopausal women with FSAD and found improved clitoral blood flow and subjective arousal scores compared with placebo (N=33) [10]. Many participants in that trial were using hormonal contraceptives. No interaction-related adverse events were reported.

Tadalafil is also studied in pulmonary arterial hypertension (PAH) under the brand name Adcirca at 40 mg daily. The PHIRST trial (N=405) included women of reproductive age, some of whom used hormonal contraceptives during the study period [11]. The trial's safety data did not identify any signal of contraceptive failure or hormonal disruption among participants receiving tadalafil.

These data points, while not designed as formal interaction studies, add clinical weight to the FDA pharmacokinetic data. Women who are prescribed tadalafil off-label can continue their chosen contraceptive method without modification.

Drugs That Actually Do Interact With Tadalafil

Understanding which drugs do interact with tadalafil helps contextualize why hormonal contraceptives do not. The FDA label identifies several categories of concern [1]:

Strong CYP3A4 inhibitors. Ketoconazole 400 mg daily increased tadalafil AUC by 312% and Cmax by 15% in a pharmacokinetic study [1]. Ritonavir, itraconazole, and clarithromycin produce similar magnification. When tadalafil is combined with these agents, the recommended maximum dose drops to 10 mg every 72 hours for as-needed use.

CYP3A4 inducers. Rifampin reduced tadalafil AUC by 88% in clinical testing [1]. This near-complete elimination of drug exposure can render tadalafil ineffective. Other potent inducers include phenytoin, carbamazepine, and phenobarbital.

Nitrates. This is the most dangerous interaction. Tadalafil potentiates the hypotensive effect of organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) through additive cGMP-mediated vasodilation [4]. Co-administration is absolutely contraindicated because of the risk of severe, potentially fatal hypotension.

Alpha-blockers. Combining tadalafil with alpha-1 adrenergic blockers such as tamsulosin or doxazosin can produce additive blood pressure reduction [1]. The FDA recommends initiating tadalafil at 5 mg if the patient is already on a stable alpha-blocker dose.

Hormonal contraceptives share none of these interaction mechanisms. They are not strong CYP3A4 modulators, they do not affect the nitric oxide/cGMP pathway, and they have no alpha-adrenergic activity.

Monitoring and Patient Counseling

No special monitoring is required when tadalafil and hormonal contraceptives are used together. Standard clinical guidance applies to each drug independently.

For tadalafil, the prescriber should confirm the absence of contraindicated medications (nitrates, ritonavir at full dose for HIV), assess cardiovascular fitness for sexual activity per the Princeton III Consensus recommendations [12], and review hepatic function if the patient has liver disease (since CYP3A4 metabolism is hepatically dependent).

For hormonal contraceptives, the prescriber should follow the CDC's U.S. Medical Eligibility Criteria for Contraceptive Use (US MEC), confirming that no category 3 or 4 conditions exist for the patient's chosen method [13]. Smoking status, migraine history with aura, and thromboembolic risk factors should be assessed per standard protocols.

Patient counseling should address one common misconception directly: tadalafil does not reduce contraceptive effectiveness. The drug does not induce CYP3A4, does not accelerate ethinyl estradiol clearance, and does not affect progestin levels. A patient who misses contraceptive pills should follow the standard missed-pill protocol regardless of tadalafil use.

If the patient is taking tadalafil alongside a strong CYP3A4 inhibitor (such as certain antiretrovirals or azole antifungals), the tadalafil dose should be reduced per label guidance, but the contraceptive regimen still requires no change [1].

Special Populations: Hepatic Impairment and Polypharmacy

Patients with mild to moderate hepatic impairment (Child-Pugh A or B) metabolize tadalafil more slowly. The FDA recommends a maximum dose of 10 mg for as-needed use in these patients [1]. Hormonal contraceptives are generally category 2 (advantages outweigh risks) in compensated cirrhosis per the US MEC [13], though combined hormonal methods become category 4 in decompensated liver disease.

In patients with hepatic impairment who take both tadalafil and hormonal contraceptives, the CYP3A4 metabolic capacity is reduced overall. Even so, the two drugs do not compete for CYP3A4 binding in a way that produces measurable changes in either drug's exposure. The lack of interaction observed in healthy volunteers is expected to hold in hepatic impairment because the interaction is absent at the molecular level, not merely masked by high metabolic capacity.

Polypharmacy scenarios deserve attention. A patient taking tadalafil, a hormonal contraceptive, and a moderate CYP3A4 inhibitor (such as erythromycin, fluconazole 200 mg, or diltiazem) may experience a modest rise in tadalafil levels. The FDA label notes that erythromycin 500 mg three times daily increased tadalafil AUC by 107% [1]. In such three-drug combinations, the interaction of concern is between tadalafil and the CYP3A4 inhibitor. The contraceptive remains uninvolved.